Table 3. Prevalence and levels of autoantibodies in serum of patients with central and peripheral NPSLE, and non-NPSLE at baseline and 6 months.
| Autoantibodies positive, No. (%) | Central NPSLE Baseline (n = 34) | Central NPSLE 6 months (n = 34) | P (%) | Peripheral NPSLE Baseline (n = 5) | Peripheral NPSLE 6 months (n = 5) | P (%) | Non-NP-SLE baseline (n = 40) | Non-NP-SLE 6 months (n = 40) | P (%) |
| Antinuclear | 28 (82) | 25 (74) | 0.38 | 4 (80) | 4 (80) | 1.0 | 40 (100) | 31 (77) | 0.001 |
| Anti-ds DNA | 27 (79) | 20 (58) | 0.07 | 5 (100) | 3 (60) | 0.22 | 30 (75) | 28 (70) | 0.62 |
| Anti-ribosomal | 21 (61) | 16 (47) | 0.22 | 4 (80) | 5 (100) | 1.0 | 13 (33) | 13 (33) | 1.0 |
| Anti-cardiolipin, IgG | 5 (15) | 5 (15) | 1.0 | 2 (40) | 1 (20) | 1.0 | 11 (28) | 9 (23) | 0.60 |
| Anti-B2-Glycoprotein I, IgG | 22 (65) | 17 (50) | 0.22 | 4 (80) | 5 (100) | 1.0 | 23 (58) | 19 (48) | 0.36 |
| Anti-N-Methyl-D-Aspartate Receptor (NMDAR)A | 8 (35) | 7 (30) | 0.75 | 0 (0) | 2 (40) | 0.44 | 12 (30) | 10 (25) | 0.62 |
| Autoantibodies levels B | |||||||||
| Anti-ds DNA | 238.8±519.9 | 41.6±76.7 | 0.06 | 163.9±292.5 | 37.9±38.7 | 0.22 | 533.04±722.2 | 162.1±399.5 | 0.008 |
| Anti-ribosomal | 96.0±157.8 | 46.5±87.3 | 0.08 | 106.9±188.7 | 25.8±19.8 | 1.0 | 69.3±98.7 | 63.5±105.2 | 0.10 |
| Anti-cardiolipin, IgG | 51.3±70.4 | 13.6±5.5 | 0.13 | 18.5±8.4 | 18.2±11.4 | 0.65 | 31.7±31.6 | 12.8±9.6 | 0.01 |
| Anti-B2-Glycoprotein I, IgG | 17.0±51.6 | 4.6±4.4 | 0.03 | 8.9±7.6 | 5.6±1.5 | 0.46 | 5.5±4.5 | 4.9±4.2 | 0.70 |
| Anti-N-Methyl-D-Aspartate Receptor (NMDAR) | 31.0±13.0 | 24.5±13.7 | 0.02 | – | – | – | 39.67±11.66 | 50.23±23.5 | 0.28 |
A
The NMDAR antibody was measured in 23 central and 5 peripheral NPSLE, and in 40 non-NPSLE patients at baseline and 6 months.
B
Only patients who scored positive at baseline for the specific antibody were considered, Central NPSLE/Peripheral NPSLE/non-NPSLE: anti-dsDNA 27/5/30, anti-ribosomal P 21/4/13, anticardiolipin IgG 5/2/11, anti-β2-glycoprotein-I 22/4/23, anti-NMDAR 8/0/12.